The 2010 JP Morgan conference kicked off yesterday with Celgene and Roche taking honors as one and two at the podium in the Westin's Grand Ballroom. It was standing room only--after all Celgene is the stock to watch for certain analysts and EVERYONE wants to know how the privatization of Genentech has succeeded. But the squeeze was more a function of half the room's chairs being spirited away than a whopping attendance.
What did this blogger learn?
Celgene put up some pretty astonishing numbers: 20% revenue growth ; 30% earnings growth; $1 billion in operational cash flow. And it was all, unsurprisingly, thanks to its multiple myeloma drug Revlimid.
Original Article: The IN VIVO Blog: Notes From JP Morgan: Sliding Toward Innovation?
